BioVentix PLC Director/PDMR Shareholding (9513U)

TIDMBVXP

RNS Number : 9513U

BioVentix PLC

28 November 2023

Bioventix plc

("Bioventix" or "the Company")

Director Dealing

Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces that the Company was notified on 28 November 2023 that on 27 November 2023 Bruce Hiscock, Chief Financial Officer of the Company, purchased a total of 17 ordinary shares of 5 pence each in the Company ("Ordinary Shares"), at an average price of 3,977 pence per Ordinary Share (the "Purchase"). The Ordinary Shares were purchased under a dividend reinvestment plan ("DRIP").

Following the Purchase, Bruce Hiscock has a beneficial interest in 778 Ordinary Shares, representing approximately 0.01 per cent. of the issued share capital of the Company.

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further details.

For further information please contact:

 
Bioventix plc                                           Tel: [phone] 
 Peter Harrison                Chief Executive Officer   001 
 
Cavendish Capital Markets                               Tel: [phone] 
 Limited                       Corporate Finance         0500 
 Geoff Nash / Simon Hicks      ECM 
 Nigel Birks / Harriet Ward 
 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 
1   Details of the person discharging managerial responsibilities 
     / person closely associated 
a)  Name                            Bruce Hiscock 
    ------------------------------  ---------------------------------------- 
2.  Reason for the Notification 
    ------------------------------------------------------------------------ 
a)  Position/status                 Chief Financial Officer 
    ------------------------------  ---------------------------------------- 
b)  Initial notification/Amendment  Initial notification 
    ------------------------------  ---------------------------------------- 
3.  Details of the issuer, emission allowance market participant, 
     auction platform, auctioneer or auction monitor 
    ------------------------------------------------------------------------ 
a)  Name                            Bioventix plc 
    ------------------------------  ---------------------------------------- 
b)  LEI                             213800225MHX7LZQY108 
    ------------------------------  ---------------------------------------- 
4.  Details of the transaction(s): section to be repeated 
     for (i) each type of instrument; (ii) each type of transaction; 
     (iii) each date; and (iv) each place where transactions 
     have been conducted 
    ------------------------------------------------------------------------ 
a)  Description of the              Ordinary Shares of 5 pence each 
     Financial instrument, 
     type of instrument 
    Identification code             GB00B4QVDF07 
    ------------------------------  ---------------------------------------- 
b)  Nature of the transaction       Purchase of Ordinary Shares 
    ------------------------------  ---------------------------------------- 
c)  Price(s) and volume(s)          17 Ordinary Shares 
                                     3,977 pence 
    ------------------------------  ---------------------------------------- 
d)  Aggregated information:         Purchase of 17 Ordinary Shares at 3,977 
                                     pence each 
      *    Aggregated volume 
 
 
 
      *    Price 
    ------------------------------  ---------------------------------------- 
e)  Date of the transaction         27 November 2023 
    ------------------------------  ---------------------------------------- 
f)  Place of the transaction        London Stock Exchange, AIM Market (XLON) 
    ------------------------------  ---------------------------------------- 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHEASFPAAKDFFA

(END) Dow Jones Newswires

November 28, 2023 10:26 ET (15:26 GMT)